MCM
SGMO

MAI Capital Management’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History

MAI Capital Management’s Portfolio SGMO Stock Details SGMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$25 Hold
100
– – ﹤0.01% 4940
2025
Q4 		$42 Hold
100
– – ﹤0.01% 4254
2025
Q3 		$68 Hold
100
– – ﹤0.01% 3757
2025
Q2 		$55 Hold
100
– – ﹤0.01% 3912
2025
Q1 		$66 Hold
100
– – ﹤0.01% 3380
2024
Q4 		$102 Buy
+100
New +$183 ﹤0.01% 3422

Other funds holding SGMO

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

MAI Capital Management's SGMO Position: Q1 2026 in Review

MAI Capital Management held its SANGAMO THERAPEUTICS INC (SGMO) position steady in Q1 2026 at 100 shares worth $25. The position accounts for ﹤0.01% of the portfolio, ranked #4940.

MAI Capital Management first reported a position in SGMO in Q4 2024 and has held it in 6 quarters since. The position peaked at $102 in Q4 2024. 112 funds tracked by Wall St. Rank hold SGMO as of Q1 2026.

  • MAI Capital Management held 100 shares of SANGAMO THERAPEUTICS INC worth $25 as of Q1 2026.
  • MAI Capital Management left its SANGAMO THERAPEUTICS INC share count unchanged in Q1 2026.
  • SANGAMO THERAPEUTICS INC made up ﹤0.01% of MAI Capital Management's portfolio in Q1 2026, its #4940 holding.
  • MAI Capital Management first reported a position in SANGAMO THERAPEUTICS INC in Q4 2024 and has held it in 6 quarters since.
  • MAI Capital Management's SANGAMO THERAPEUTICS INC position peaked at $102 in Q4 2024.
  • 112 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q1 2026.

Based on MAI Capital Management's 13F filing for Q1 2026, filed 15 May 2026.